Advertisement
UK markets closed
  • FTSE 100

    8,146.86
    -16.81 (-0.21%)
     
  • FTSE 250

    20,120.36
    -75.59 (-0.37%)
     
  • AIM

    776.04
    -4.39 (-0.56%)
     
  • GBP/EUR

    1.1845
    -0.0034 (-0.29%)
     
  • GBP/USD

    1.2686
    -0.0075 (-0.59%)
     
  • Bitcoin GBP

    52,191.88
    -784.91 (-1.48%)
     
  • CMC Crypto 200

    1,402.43
    -15.45 (-1.09%)
     
  • S&P 500

    5,431.60
    -2.14 (-0.04%)
     
  • DOW

    38,589.16
    -57.94 (-0.15%)
     
  • CRUDE OIL

    78.49
    -0.13 (-0.17%)
     
  • GOLD FUTURES

    2,348.40
    +30.40 (+1.31%)
     
  • NIKKEI 225

    38,814.56
    +94.09 (+0.24%)
     
  • HANG SENG

    17,941.78
    -170.85 (-0.94%)
     
  • DAX

    18,002.02
    -263.66 (-1.44%)
     
  • CAC 40

    7,503.27
    -204.75 (-2.66%)
     

Global Oncolytic Virus Therapy Market Report 2023: Increase in Clinical Trials and Approval of New Virus Therapies Boosts Growth

Company Logo
Company Logo

Dublin, May 11, 2023 (GLOBE NEWSWIRE) -- The "Global Oncolytic Virus Therapy Market Outlook to 2035" report has been added to ResearchAndMarkets.com's offering.

The global oncolytic virus therapy market is anticipated to grow with a CAGR of 27.07 % over the forecast period, i.e., 2023 - 2035.

Factors such as the increasing prevalence of cancer cases worldwide, followed by the increasing healthcare expenditure and rising investment in cancer research & development are projected to drive the growth of the market in the coming years.

Additionally, the increase in clinical trials and approval of new virus therapies are also expected to boost the market growth. The market is estimated to garner a revenue of about USD 1,150 million by the end of 2035, up from a revenue of about USD 85 million in the year 2022.

The global oncolytic virus therapy market is segmented into numerous segments, which include segmentation by therapy type, virus type, indication, demography, end-user, and by region.

ADVERTISEMENT

By therapy type, the market is segmented into HSV-based, adenovirus-based, reovirus, poxviruses, NDV (Newcastle disease virus), and others.

By the end of 2035, the HSV-based oncolytic virus therapy segment is anticipated to garner the largest revenue of close to USD 375 Million. HSV helps in expressing immune evasion genes for instance ICP34.5, ICPo, US3, which are focused in inducing and activating host responses to evade the immune system and establish effective long-term latent infection.

However, after various research in immunotherapy, it has been observed that treatment of melanoma via herpes simplex virus can address the challenge of the host's innate antiviral defense mechanism by redirecting these immune cells to attack tumor cells instead via arming the HSV-based oncolytic virus. This has resulted in HSV type-1 in gaining maximum attention owing to the growth of the market's segment.

On the basis of region, the global oncolytic virus therapy market is segmented into North America, Europe, Asia Pacific, and Rest of the World.

The market in North America, amongst the market in all the other regions, is anticipated to garner the largest revenue of nearly USD 535 Million by the end of 2035.

Moreover, in the year 2022, the market in the region generated a revenue of over USD 30 Million. An increasing demand for targeted therapies among the people, and the rising cancer cases in the country are anticipated to create a surge in demand for oncolytic virus therapies in the forthcoming years.

Further, the country's improved research infrastructure and increasing investment in R&D in the healthcare industry alongside the government's initiatives are also some of the essential driving factors for market development over the forecast period.

Key Topics Covered:

1. An Outline of the Oncolytic Virus Therapy Market

2. Assumptions and Acronyms

3. Research Methodology

4. Summary of the Report for Key Decision Marker

5. Forces of the Market Constituents

6. Key Market Opportunities for Business Growth
6.1. Based on the Therapy Type
6.2. Based on the Virus Therapy
6.3. Based on the Indication
6.4. Based on Demography
6.5. Based on the End-User
6.6. Based on Geographical Presence

7. Major Roadblocks for the Market Growth

8. Government Regulation: How They Would Aid Business?
8.1. FDA
8.2. Others

9. Industry Risk Analysis

10. Global Economic Outlook: Challenges for Global Recovery and Market
10.1. Ukraine-Russia Crisis
10.2. Potential US Economic Slowdown

11. Impact of COVID-19 on Global Oncolytic Virus Therapy Market
11.1. Impact on Oncolytic Virus Therapy Manufacturers
11.2. Impact on End Users
11.3. Impact on Demand

12. Pipeline Analysis

13. Oncolytic Virus Platforms Under Evaluation
13.1. Adenovirus
13.2. Herpes Simplex Virus
13.3. Maraba Virus
13.4. Measles
13.5. Newcastle Disease Virus
13.6. Other

14. Epidemiology Analysis

15. Analysis on the Oncolytic Virus Therapy

16. Competitive Landscape

17. Global Oncolytic Virus Therapy Market Outlook & Projections, Opportunity Assessment, 2022 to 2035

18. North America Oncolytic Virus Therapy Market Outlook & Projections, Opportunity Assessment, 2022 to 2035

19. Asia Pacific Oncolytic Virus Therapy Market Outlook & Projections, Opportunity Assessment, 2022 to 2035

20. Europe Oncolytic Virus Therapy Market Outlook & Projections, Opportunity Assessment, 2022 to 2035

21. Rest of World Oncolytic Virus Therapy Market Outlook & Projections, Opportunity Assessment, 2022 to 2035

Companies Mentioned

  • Amgen Inc.

  • Shanghai Sunway Biotech Co. Ltd.

  • Oncolys BioPharma Inc.

  • TILT Biotherapeutics Ltd.

  • Oncorus Inc.

  • Takara Bio Inc.

  • Vyriad

  • Transgene sa

  • Lokon Pharma AB

  • Pfizer Inc.

  • Rigvir Group

  • Shenzhen Sibiono GeneTech

  • Oncolytics Biotech Inc

  • Daiichi Sankyo

  • Kissei Pharmaceutical Co. Ltd.

  • Boehringer Ingelheim

For more information about this report visit https://www.researchandmarkets.com/r/hk80vz

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900